Group 1 - The core viewpoint of the report is that Tencent Holdings (0700.HK) maintains a "Buy" rating with a target price of HKD 750.0, indicating confidence in the company's future performance [1] - The company's 4Q25 performance met expectations, showcasing robust core business operations [1] - Increased investment in AI is expected to enhance long-term competitiveness, despite potential short-term profit suppression in FY26E [1] Group 2 - Growth momentum is clearly evident in the gaming, advertising, and cloud business sectors [1] - The Sum-of-the-Parts (SOTP) valuation provides support for the company's stock price [1]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2026】566号 为促进招商中证光伏产业交易型开放式指数证券投资基金（以下简称光伏招商，基金代 码:516230）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上 市基金做市业务》等相关规定，本所同意招商证券股份有限公司自2026年03月23日起为光伏招商提供主 做市服务。 特此公告。 上海证券交易所 2026年03月20日 ...

Core Viewpoint - Century Huatong (002602.SZ) experienced a closing price of 16.18 yuan, reflecting a decline of 2.82% [1] Group 1: Company Performance - Research analysts from China Merchants Securities, Gu Jia and Xie Xiaoyan, published a report on February 2, stating that Century Huatong is a global leader in mobile gaming with significant profit growth over 25 years [1] - The report maintained a "strongly recommended" investment rating for Century Huatong [1] - On February 3, Century Huatong's stock closed at 20.38 yuan, but the stock price has been fluctuating downward over the following month [1]

招商证券主要观点如下： 浆料是电池制造的关键材料，影响电池效率表现 太阳能电池整体结构基于大面积的PN结，在光照条件下光生电子将通过印刷在电池表面的细栅、主栅 汇集，经由焊带至外电路对外做功，实现光能向电能的转化。电池片正背面栅线由浆料印刷制成，实现 电池片层级的汇流，按形态、功能分为细栅、主栅，其图形设计影响电池受光量，材料配方等影响复合 表现，决定其等效电阻，因而浆料对光伏电池光电转换效率及组件性能表现极为关键。 "银"大于"硅"，降银提供最大的潜在降本空间 过去电池浆料以银体系为主，银价大幅上涨后，电池非硅成本中浆料占比跃升，以主流TOPCon电池为 例，单瓦成本由6分左右跃升至0.1-0.2元(考虑银价波动)，已经超过硅料，成为电池成本第一大项，降银 单耗成为产业链降本的重点。 智通财经APP获悉，招商证券发布研报称，近年来银价持续上升，尤其2025年大涨后浆料成本占比已经 超过硅料，且银价大幅波动对产业链盈利影响巨大，贱金属替代更加迫切。结合产业反馈当前在粉体、 浆料、电池环节的深度合作下铜代银已取得积极进展，若顺利产业化各参与环节均有望获得丰厚回报， 同时考虑周期底部技术扩散节奏更慢，浆料技术变革 ...

转自：智通财经 【招商证券(香港)：维持腾讯控股买入评级 目标价750港元】智通财经3月20日电，招商证券(香港)发布 关于腾讯控股（00700.HK）的研报，维持"买入"评级，目标价750.0港元。公司4Q25业绩符合预期，核 心业务稳健，AI投资加码有望强化长期竞争力。虽FY26E AI投入或压制短期利润，但游戏、广告及云 业务增长动能明确，SOTP估值具支撑。 ...

Core Viewpoint - The report from China Merchants Securities International lowers the target price for Tencent Holdings (00700) from HKD 766 to HKD 700, a decrease of 8.6%, while maintaining an "Overweight" investment rating [1][4]. Financial Performance - Tencent's Q4 performance for the previous year met expectations, leading to a 6% downward revision in the earnings forecast for the fiscal years 2026-27, primarily due to increased investments in artificial intelligence (AI) [1][4]. - The projected revenue and adjusted net profit growth for Tencent in fiscal year 2026 is estimated at 10% and 8%, respectively, with the new target price corresponding to a 21 times forecasted price-to-earnings (P/E) ratio for that year [1][4]. Valuation Comparison - Tencent's current valuation for fiscal years 2026/27 stands at 16 times and 14 times forecasted P/E ratios, which is in line with the company's historical average [1][4]. - In comparison, Chinese peers are valued at 14 times and 11 times, while U.S. peers are at 24 times and 20 times [1][4]. Growth Drivers - The report highlights several growth drivers for Tencent, including a strong social network moat, advancements in AI technology, accelerated advertising business, new game launches (e.g., "Honor of Kings: World" expected in April), commercialization of AI products, overseas opportunities, and profit margin improvements driven by AI [1][4].

Core Viewpoint - The report from China Merchants Securities International indicates a reduction in the target price for Tencent Holdings (00700) from HKD 766 to HKD 700, representing an 8.6% decrease, while maintaining an "Overweight" investment rating [1] Financial Performance - Tencent's Q4 performance for the previous year met expectations, leading to a downward revision of the earnings forecast for the fiscal years 2026-27 by 6% due to increased investments in the AI sector [1] - The projected revenue and adjusted net profit growth for Tencent in the fiscal year 2026 is estimated at 10% and 8%, respectively, with the new target price corresponding to a 21 times forecasted price-to-earnings ratio for 2026 [1] Valuation Comparison - Tencent's current valuation for the fiscal years 2026/27 stands at 16 times and 14 times forecasted price-to-earnings ratios, which aligns with the company's historical average [1] - In comparison, Chinese peers are valued at 14 times and 11 times, while U.S. peers are at 24 times and 20 times [1] Growth Drivers - The report highlights several growth drivers for Tencent, including a strong social network moat, advancements in AI technology, accelerated advertising business, new game launches (e.g., "Honor of Kings: World" expected in April), commercialization of AI products, overseas opportunities, and profit margin improvements driven by AI [1]

Group 1 - The core point of the news is that Aibo Medical (688050.SH) announced a share reduction plan by shareholder Mao Liping, who intends to reduce up to 1,934,000 shares, representing no more than 1% of the company's total share capital, through block trading within a specified period [1] - As of the announcement date, Mao Liping holds 5,604,413 shares, accounting for 2.90% of the total share capital, and together with his concerted actor Bai Ying, they hold a total of 11,304,459 shares, which is 5.85% of the total share capital [1] - Mao Liping's shares were acquired before the company's IPO and through capital reserve conversion, with specific shares becoming tradable on July 31, 2023, and June 5, 2024 [1] Group 2 - Aibo Medical's stock price hit a record low of 53.00 yuan during trading, marking the lowest price since its listing [2] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 29, 2020, with an initial issuance of 26.29 million shares at a price of 33.55 yuan per share, raising a total of 882 million yuan [2] - The net proceeds from the fundraising amounted to 804 million yuan after deducting issuance costs, which were used for various projects including capacity expansion and R&D for high-end ophthalmic medical devices [2] Group 3 - The company successfully issued 3,593,615 shares at a price of 79.20 yuan per share, raising a total of approximately 284.61 million yuan, with a net amount of about 280.61 million yuan after deducting issuance costs [3] - The total amount raised from the two fundraising activities is approximately 1.167 billion yuan [4]

Group 1 - The core viewpoint of the report emphasizes that the securities industry is experiencing a recovery in valuation, driven by favorable industry conditions and potential policy reforms [4][5][34] - The report highlights that since the "924" market rally in 2024, the A-share securities index has significantly outperformed the Shanghai Composite Index, achieving a peak excess return of 35.1% [5][10] - The report identifies three main factors contributing to the underperformance of the securities sector since 2025: sustainability concerns regarding high growth expectations, the impact of refinancing on valuation, and pressures from the funding environment [15][19][24] Group 2 - The report forecasts a robust growth of approximately 10% in the securities sector's net profit for 2026, building on a high base from 2025 [34][37] - It discusses the shift in the securities business model towards wealth management and large investment banking, indicating a transition from traditional brokerage and proprietary trading to more stable revenue sources [40][41] - The report outlines the expected impact of policy reforms aimed at enhancing the role of securities firms as core intermediaries in the capital market, with a focus on increasing direct financing [46][49]

Group 1 - The core point of the news is that Aibo Medical (688050.SH) announced a share reduction plan by shareholder Mao Liping, who intends to reduce his holdings by up to 1,934,000 shares, representing no more than 1% of the company's total share capital [1] - As of the announcement date, Mao Liping holds 5,604,413 shares, accounting for 2.90% of the total share capital, while together with his concerted actor Bai Ying, they hold a total of 11,304,459 shares, which is 5.85% of the total share capital [1] - Mao Liping's shares were acquired before the company's IPO and through capital reserve conversion after the listing, with these shares set to be tradable on July 31, 2023, and June 5, 2024, respectively [1] Group 2 - Aibo Medical's stock price hit a record low of 53.00 yuan during trading, marking the lowest price since its listing [2] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 29, 2020, with an issuance of 26.29 million shares at a price of 33.55 yuan per share, raising a total of 882 million yuan [2] - The net proceeds from the fundraising amounted to 804 million yuan after deducting issuance costs, which were 78.04 million yuan, with the lead underwriter being China Merchants Securities [2] Group 3 - The company issued 3,593,615 shares at a price of 79.20 yuan per share, raising a total of 284,614,308 yuan, with net proceeds of 280,612,310.30 yuan after deducting issuance costs [3] - The total amount raised from the two fundraising events is 1.167 billion yuan [4]